BURZYNSKI RESEARCH INSTITUTE INC SEC 10-Q Report
閱讀1分鐘
Burzynski Research Institute Inc., a company dedicated to the research and development of Antineoplaston drugs for cancer treatment, has released its Form 10-Q report for the second quarter of fiscal year 2025. The report highlights the company's financial performance and operational challenges, providing insights into its current status and future outlook.
Financial Highlights
- Net Loss: $(331,451). The net loss for the three months ended May 31, 2025, decreased compared to the same period in 2024, primarily due to a decrease in general and administrative expenses.
- Basic and Diluted Loss Per Common Share: $(0.00). The loss per share remained unchanged from the previous year, reflecting the consistent number of shares outstanding and the net loss incurred.
Business Highlights
- Research and Development Focus: The company is primarily engaged in the research and development of Antineoplaston drugs for cancer treatment. The clinical trials are currently under a full clinical hold by the FDA, which restricts the enrollment of new patients.
- Clinical Trial Status: The company's investigational new drug application (IND) 43742 is under a full clinical hold, preventing new patient enrollment. This hold is due to unresolved issues related to the manufacturing facility and previous adverse events.
- License Agreement: A new license agreement was entered into on May 22, 2023, granting the company exclusive rights in the U.S. and Canada to exploit Antineoplaston-related products and services, pending FDA approval.
- Economic Dependency: The company is economically dependent on Dr. Burzynski for funding its operations. Dr. Burzynski's medical practice has been the primary source of funding, and any cessation of this support could jeopardize the company's ability to continue operations.
- Future Outlook: The company anticipates spending approximately $900,000 in the remaining quarters of the fiscal year ending February 28, 2026. The continuation of operations is heavily reliant on Dr. Burzynski's ongoing financial support.
- Operational Challenges: The company faces significant operational challenges due to the FDA's clinical hold and the dependency on a single funding source. These factors contribute to uncertainty regarding the company's ability to sustain its research activities.
SEC Filing: BURZYNSKI RESEARCH INSTITUTE INC [ BZYR ] - 10-Q - Jul. 15, 2025